Monopar Therapeutics Inc. Common Stock (MNPR) Stock Price

MNPRStock
$111.89+210.29%52W
Market Cap$751.02M
P/E
PEG Ratio
Div yield
Beta1.42

MNPR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)82.26%
Price vs S&P 500 (4W)-1.32%
VGM Score89.10

MNPR Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.65-$0.62+4.46%(+$0.03)
Q1 2026-$0.90-$0.46+48.75%(+$0.44)
Q4 2025-$0.51-$0.61-19.08%(-$0.10)
Q3 2025-$0.40-$0.48-20.33%(-$0.08)
Q2 2025-$0.48-$0.35+27.59%(+$0.13)

MNPR Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.20
4.16
4.16
4.16

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
MNPRMonopar Therapeutics Inc. Common Stock
A$111.89
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Monopar Therapeutics Inc. Common Stock

Monopar Therapeutics is a clinical-stage biopharmaceutical company developing oncology therapeutics with a diversified pipeline spanning multiple development stages. The company's programs include Validive for chemoradiotherapy-induced oral mucositis in oropharyngeal cancer, camsirubicin for soft tissue sarcoma, the preclinical antibody MNPR-101 for cancers and severe COVID-19, and the early-stage analog MNPR-202 for multiple cancer types.